207 results on '"Braconi, C"'
Search Results
2. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
3. Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice
4. Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer
5. Sorafenib for the Treatment of Advanced Hepatocellular Cancer – a UK Audit
6. Heterogeneity of Cholangiocarcinoma immune biology
7. Cholangiocarcinoma 2020: the next horizon in mechanisms and management
8. Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Resected Perihilar Cholangiocarcinoma, the ENS-CCA Registry
9. Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial
10. 59TiP Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)
11. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer
12. Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients
13. KIT and PDGFRα mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study
14. The impact of gender and immune system determinants on long-term survival in biliary tract cancer
15. Cholangiocarcinoma 2020: the next horizon in mechanisms and management
16. Cholangiocarcinoma 2020: the next horizon in mechanisms and management
17. O-2 Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)
18. Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer
19. 80TiP Global phase III study of NUC-1031 plus cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)
20. Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of response to DNA damage
21. Detection of microRNAs as biomarker for anti-EGFR antibody resistance in colon cancer patients
22. Liver metastases (LM) from intrahepatic cholangiocarcinoma (iCCA): Outcomes from the European Network for the study of cholangiocarcinoma (ENS-CCA) registry and implications on current American Joint Committee on Cancer (AJCC) staging
23. Identification of a nanostring signature that differentiates early pancreatic cancers according to stromal composition and predicts clinical outcome
24. MicroRNAs: nuovi biomarcatori predittivi di sviluppo di insufficienza renale cronica e ipertensione arteriosa nei pazienti sottoposti a nefrectomia radicale per carcinoma renale
25. MicroRNAs as predictive biomarkers of chronic kidney disease (CKD) in patients (pts) undergoing radical nephrectomy (RN) for kidney cancer
26. Clinical and pre-clinical biomarkers of Regorafenib (REG) efficacy in metastatic colorectal cancer (mCRC) in a phase II trial
27. Regulation of miR-483-3p by the O-linked N-acetylglucosamine transferase links chemosensitivity to glucose metabolism in liver cancer cells
28. KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial
29. 14P - Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of response to DNA damage
30. 1953P - Detection of microRNAs as biomarker for anti-EGFR antibody resistance in colon cancer patients
31. 731P - Liver metastases (LM) from intrahepatic cholangiocarcinoma (iCCA): Outcomes from the European Network for the study of cholangiocarcinoma (ENS-CCA) registry and implications on current American Joint Committee on Cancer (AJCC) staging
32. PD-003 - Identification of a nanostring signature that differentiates early pancreatic cancers according to stromal composition and predicts clinical outcome
33. Investigating the feasibility of precision medicine in gastrointestinal cancers
34. MicroRNAs as biomarkers of resistance to HER2 inhibitors in combination with chemotherapy in gastro-oesophageal cancer cell lines
35. Prognostic value of the immune-related transcriptome in biliary tract cancers
36. KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial
37. HSP-90 Inhibition is a Promising Therapeutic Strategy in Cholangiocarcinoma and MIR-21 may Serve as a Biomarker of Sensitivity
38. Prognostic role of the LCS-6 KRAS variant in locally advanced rectal cancer : Results of the EXPERT-C trial
39. Anti-miR-135b in colon cancer treatment: Results from a preclinical study
40. Diabete e tratti ossessivo-compulsivi di personalità
41. Retrospective analysis of the role of adjuvant chemotherapy and microRNAs expression in resected cholangiocarcinomas (CCAs)
42. 2188 Prognostic role of the LCS-6 KRAS variant in locally advanced rectal cancer: Results of the EXPERT-C trial
43. P0282 : The long non coding RNA UC.158 modulates growth of Wnt/β;-catenin driven hepatocellular carcinoma (HCC)
44. Ipotesi di impiego dell'acido rumenico nel trattamento del diabete di tipo 2
45. 116P - Clinical and pre-clinical biomarkers of Regorafenib (REG) efficacy in metastatic colorectal cancer (mCRC) in a phase II trial
46. Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer
47. P64 THE ULTRACONSERVED NON CODING RNA UC.158 IS DOWNSTREAM OF THE WNT/b-CATENIN PATHWAY IN LIVER CANCERS
48. 1595P - MicroRNAs as biomarkers of resistance to HER2 inhibitors in combination with chemotherapy in gastro-oesophageal cancer cell lines
49. 694P - Prognostic value of the immune-related transcriptome in biliary tract cancers
50. 638P - Investigating the feasibility of precision medicine in gastrointestinal cancers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.